The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.
Lancet Gastroenterol HepatolJul 21, 2026 (epub)
Mazen Noureddin, Winston Dunn, Rashmee Patil et al.
✦ AI-curated · Sources linked
In 30 seconds
The DD01-DN-02 trial, a randomized, double-blind, multicentre, placebo-controlled phase 2 study, evaluated the dual agonist DD01 in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or steatohepatitis (MASH). At 12 weeks, 76% of participants receiving DD01 achieved a 30% or greater reduction in liver fat compared to 12% in the placebo group (p<0.0001).
Key findings
- 76% of participants on DD01 had a 30% or greater reduction in liver fat at week 12.
- Only 12% of placebo participants achieved the same reduction.
- Treatment-emergent adverse events occurred in 85% of DD01 participants.
- Serious adverse events were reported in 6% of the DD01 group.
Why it matters
The findings suggest that DD01 may significantly reduce liver fat in patients with MASLD and MASH, indicating potential for improved management of these conditions associated with obesity and metabolic syndrome.